Emergence of ceftolozane-tazobactam-resistant Pseudomonas aeruginosa during treatment is mediated by a single AmpC structural mutation

Shawn H. MacVane; Ruchi Pandey; Lisa L. Steed; Barry N. Kreiswirth; Liang Chen

doi:10.1128/AAC.01183-17

Emergence of ceftolozane-tazobactam-resistant Pseudomonas aeruginosa during treatment is mediated by a single AmpC structural mutation

Shawn H. MacVane
, Ruchi Pandey
, Lisa L. Steed
, Barry N. Kreiswirth
, Liang Chen

Medical University of South Carolina
Rutgers - The State University of New Jersey, Newark

Research output: Contribution to journal › Article › peer-review

79 Scopus citations

Abstract

Ceftolozane-tazobactam is a cephalosporin--lactamase inhibitor combination that exhibits potent in vitro activity against Pseudomonas aeruginosa, including strains that are resistant to other -lactams. The emergence of ceftolozane-tazobactam resistance among clinical isolates of P. aeruginosa has rarely been described. Here we characterized ceftolozane-tazobactam-resistant P. aeruginosa strains recovered from a patient who was treated with this agent for 6 weeks for a recurrent wound infection. The results showed that the resistance was mediated by a single AmpC structural mutation.

Original language	English
Article number	e01183
Journal	Antimicrobial Agents and Chemotherapy
Volume	61
Issue number	12
DOIs	https://doi.org/10.1128/AAC.01183-17
State	Published - Dec 2017

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

AmpC
Ceftolozane-tazobactam
G183D
Pseudomonas aeruginosa

Access to Document

10.1128/AAC.01183-17

Cite this

@article{ec7d9670fbb6466da9c88f42c26f37d8,

title = "Emergence of ceftolozane-tazobactam-resistant Pseudomonas aeruginosa during treatment is mediated by a single AmpC structural mutation",

abstract = "Ceftolozane-tazobactam is a cephalosporin--lactamase inhibitor combination that exhibits potent in vitro activity against Pseudomonas aeruginosa, including strains that are resistant to other -lactams. The emergence of ceftolozane-tazobactam resistance among clinical isolates of P. aeruginosa has rarely been described. Here we characterized ceftolozane-tazobactam-resistant P. aeruginosa strains recovered from a patient who was treated with this agent for 6 weeks for a recurrent wound infection. The results showed that the resistance was mediated by a single AmpC structural mutation.",

keywords = "AmpC, Ceftolozane-tazobactam, G183D, Pseudomonas aeruginosa",

author = "MacVane, \{Shawn H.\} and Ruchi Pandey and Steed, \{Lisa L.\} and Kreiswirth, \{Barry N.\} and Liang Chen",

year = "2017",

month = dec,

doi = "10.1128/AAC.01183-17",

language = "English",

volume = "61",

journal = "Antimicrobial Agents and Chemotherapy",

issn = "0066-4804",

publisher = "American Society for Microbiology",

number = "12",

}

TY - JOUR

T1 - Emergence of ceftolozane-tazobactam-resistant Pseudomonas aeruginosa during treatment is mediated by a single AmpC structural mutation

AU - MacVane, Shawn H.

AU - Pandey, Ruchi

AU - Steed, Lisa L.

AU - Kreiswirth, Barry N.

AU - Chen, Liang

PY - 2017/12

Y1 - 2017/12

N2 - Ceftolozane-tazobactam is a cephalosporin--lactamase inhibitor combination that exhibits potent in vitro activity against Pseudomonas aeruginosa, including strains that are resistant to other -lactams. The emergence of ceftolozane-tazobactam resistance among clinical isolates of P. aeruginosa has rarely been described. Here we characterized ceftolozane-tazobactam-resistant P. aeruginosa strains recovered from a patient who was treated with this agent for 6 weeks for a recurrent wound infection. The results showed that the resistance was mediated by a single AmpC structural mutation.

AB - Ceftolozane-tazobactam is a cephalosporin--lactamase inhibitor combination that exhibits potent in vitro activity against Pseudomonas aeruginosa, including strains that are resistant to other -lactams. The emergence of ceftolozane-tazobactam resistance among clinical isolates of P. aeruginosa has rarely been described. Here we characterized ceftolozane-tazobactam-resistant P. aeruginosa strains recovered from a patient who was treated with this agent for 6 weeks for a recurrent wound infection. The results showed that the resistance was mediated by a single AmpC structural mutation.

KW - AmpC

KW - Ceftolozane-tazobactam

KW - G183D

KW - Pseudomonas aeruginosa

UR - https://www.scopus.com/pages/publications/85035049407

U2 - 10.1128/AAC.01183-17

DO - 10.1128/AAC.01183-17

M3 - Article

C2 - 28947473

AN - SCOPUS:85035049407

SN - 0066-4804

VL - 61

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

IS - 12

M1 - e01183

ER -

Emergence of ceftolozane-tazobactam-resistant Pseudomonas aeruginosa during treatment is mediated by a single AmpC structural mutation

Abstract

UN SDGs

Keywords

Access to Document

Other files and links

Fingerprint

Cite this